MyoKardia’s experimental drug MYK-461, currently in Stage 2 trials for humans, has now been shown to eliminate left ventricular obstruction in five cats with HCM. It has already been shown to inhibit traits of HCM in mice.
Addressing these findings, Associate Professor Joshua Stern, chief of the Cardiology Service at the University of California, Davis, veterinary hospital, stated:
“There has been little to no progress in advancing the treatment of HCM in humans or animals for many years,” Stern said. “This study brings new hope for cats and people.”
Based on these positive results, U.C.Davis is hoping to conduct a clinical trial of MYK-461 to determine whether it could become the standard of care for cats with HCM.
The full text of the article published in Plos One can be found here.
HCM experts in the U.K. have found that extreme left ventricular wall thickness does not automatically correlate with an increased risk of sudden death. Thus, results from a recent study published in the American Heart Association’s Circulation: Arrhythmia and Electrophysiology, suggest that extreme hypertrophy NOT be the sole factor justifying the implantation of an implantable defibrillator.